Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class ASSE: 603707

"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Obtaining U.S. FDA Approval for Adalimumab Injection of Subsidiary

Sep 30, 2026 · Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Obtaining U.S. FDA Approval for Adalimumab Injection of Subsidiary

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A

"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Obtaining U.S. FDA Approval for Vitamin B1 Injection of SubsidiarySep 29
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Participation in Subscription of Private Fund Units by Wholly-owned SubsidiarySep 25
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Amikacin Sulfate InjectionSep 23
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Subsidiary's Receipt of U.S. FDA Approval for an Additional Manufacturing Site for Adalimumab InjectionSep 2

All Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A news releases